以光激活的纳米钻石为基础的药物输送系统,用于空间时空释放反意义寡核酸
Hoi Man Leung1, Ling Sum Liu2, Yuzhen Cai1
1Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon Tong, Kowloon, Hong Kong SAR, China.
Bioconjugate chemistry
|April 25, 2024
概括
这项研究开发了可光触发的纳米钻石 (NDs),用于精确的药物输送. 紫外线光触发了NDs的治疗剂的释放,增强了精确医学应用.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 纳米钻石 (ND) 显示出作为药物输送平台的前景.
- 不受控制的药物释放仍然是准确医学中NDs的一个重大挑战.
研究的目的:
- 开发可光触发的基于纳米钻石的药物输送系统.
- 为了使治疗药物的可控释放,使用光刺激.
主要方法:
- 使用正体-尼特罗 (o-NB) 分子作为药物和NDS之间的可光分裂的链接剂.
- 采用紫外线照射来切割o-NB链接器并释放反意义的寡核酸.
- 集成的光气空缺中心用于细胞追踪.
主要成果:
- 成功证明了在缓冲和细胞环境中从ND载体中释放反感性寡核酸的光触发释放.
- 展示了ND系统携带细胞不透剂的能力,绕过溶酶体降解.
- 验证了释放后反感官功能的重新激活.
结论:
- 可光分解的链接物和光刺激使得NDS的药物释放能够得到先进的,可控的释放.
- 这项技术具有针对性治疗和个性化医疗的潜力.
- NDs可以充当药物载体和细胞成像的生物探针.
相关概念视频
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


